An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
X-Chem has expanded its collaboration with Kymera Therapeutics (NASDAQ: KYMR), now the primary provider of DNA-encoded library (DEL) screening services. The partnership covers 12 targets, granting Kymera exclusive rights to discovered compounds. This collaboration aims to enhance Kymera's efforts in developing innovative protein degraders, crucial for addressing challenging disease targets. Kymera's CEO praised X-Chem’s libraries for their quality and scientific rigor, reflecting a commitment to revolutionizing medicine through targeted protein degradation.
Positive
Expanded collaboration with X-Chem enhances Kymera's drug discovery capabilities.
Exclusive rights to compounds discovered, potentially increasing Kymera's market position.
Focus on innovative protein degradation technology may lead to breakthrough therapies.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR). With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera — with X-Chem applying its world-leading DEL platform to support Kymera’s discovery of first- and best-in-class protein degraders. The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.
“Having worked with multiple DEL providers, we have been impressed with the quality of X-Chem’s libraries and their scientific rigor,” said Nello Mainolfi, Ph.D., Founder, President and CEO of Kymera Therapeutics. “Kymera’s unique target selection strategy is critical to our success, and X-Chem has been a valued partner in helping us to unlock challenging disease targets that can be only or best addressed by targeted protein degradation. We look forward to extending our collaboration and working together to discover revolutionary new medicines.”
Matt Clark, CEO of X-Chem, said, “The team at Kymera has built an amazing company that is a leader in the targeted protein degradation field. We are delighted to be able to work more closely with Kymera and help them discover more compounds that positively impact patients.”
About X-Chem
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” company by Fierce Biotech and has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston’s top workplaces. For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.
What does the recent collaboration between Kymera Therapeutics and X-Chem entail?
Kymera Therapeutics has expanded its partnership with X-Chem to include 12 targets, making X-Chem the primary provider of DNA-encoded library screening services.
What is the significance of the expanded partnership between Kymera and X-Chem?
The expanded agreement allows Kymera exclusive rights to compounds discovered, enhancing its potential in developing novel protein degraders.
When was the collaboration between Kymera and X-Chem announced?
The collaboration was announced on January 31, 2023.
How might the collaboration impact Kymera's stock (KYMR)?
The collaboration could positively impact Kymera's stock by strengthening its drug discovery pipeline and market position.
What is the focus of Kymera Therapeutics' drug discovery efforts?
Kymera Therapeutics focuses on targeted protein degradation to address challenging disease targets and improve treatment efficacy.
